Ep. 374 - Parkinson's deep dive & FDA trial reforms

BioCentury This Week by BioCentury

Jun 29, 202634:14Science & Medicine

New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...

Related Episodes

Continue listening to more episodes from BioCentury This Week.

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Aug 31, 2026 - 35:37

Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals...

Ep. 384 - Back to School Special: The global FIH trials race

Aug 27, 2026 - 42:31

China has changed the global narrative on delivering early human clinical data, with a new bar for speed...

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Aug 24, 2026 - 19:13

A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized n...

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

Aug 17, 2026 - 25:28

A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On...

Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs

Aug 10, 2026 - 31:43

Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Au...

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Aug 3, 2026 - 32:25

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal mak...

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Jul 27, 2026 - 34:09

Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Bioscience...

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

Jul 20, 2026 - 42:07

The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCent...